Case Report Cardiac Aspergilloma: A Rare Case of a Cardiac Mass
Involving the Native Tricuspid Valve, Right Atrium, and Right
Ventricle in an Immunocompromised Patient
Christina S. Chen-Milhone ,1 Kalyan Chakravarthy Potu,2 and Sudhir
Mungee2
1Department of Internal Medicine and Pediatrics, University of
Illinois College of Medicine at Peoria, Peoria, IL, USA 2Department
of Cardiology, University of Illinois College of Medicine at
Peoria, Peoria, IL, USA
Correspondence should be addressed to Christina S. Chen-Milhone;
[email protected]
Received 10 November 2017; Accepted 31 December 2017; Published 29
January 2018
Academic Editor: Tayfun Sahin
Copyright © 2018 Christina S. Chen-Milhone et al. *is is an open
access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and
reproduction in anymedium, provided the original work is properly
cited.
Aspergillus can cause devastating opportunistic infections in
immunocompromised patients. Rarely does this fungus invade the
heart, and when it does, survival is especially poor despite
optimal medical and surgical treatment. We report a case of cardiac
aspergilloma with involvement of the tricuspid valve and both the
right atrium and ventricle found on a transthoracic echo-
cardiogram in an immunocompromised patient after developing atrial
fibrillation with rapid ventricular rate. *e findings from this
case suggest that early clinical suspicion is critical in early
diagnosis and thus early treatment.
1. Introduction
Aspergillus is a common fungus in the environment that can cause
fatal diseases in humans. *e Aspergillus spores are easily inhaled,
and immunocompromised individuals are known to be more susceptible
to its disease. Acute invasive aspergillus of the heart is
particularly uncommon. Asper- gillus endocarditis accounts for
20–25% of all cases of fungal endocarditis, and fungal endocarditis
only comprises <2% of all cases of endocarditis [1, 2]. Invasive
aspergillus involving heart valves and chambers is even rarer with
only a handful of cases reported in the literature. In this report,
we present a case of cardiac aspergilloma involving the native
tricuspid valve and both the right atrium and ventricle that
initially presented as a cardiac mass in an immunocompromised
patient.
2. Case Report
A 62-year-old male presented to an outlying hospital with a
one-month history of productive cough, shortness of breath, and
intermittent fevers, and a syncopal episode one week before. His
past medical history was significant for
hypertension, prostatic adenocarcinoma with bone metas- tasis,
atrial fibrillation, and bilateral pulmonary embolism. *e prostatic
adenocarcinoma was diagnosed 11 months before, and he developed the
bilateral pulmonary embolism approximately 8 months before. He
completed 40 cycles of radiation, and medications included Zytiga
in conjunction with prednisone, Lupron, and Eliquis. He was a
former smoker and smoked a maximum of 5 cigarettes daily for 35
years. His social history was otherwise negative for high-risk
sexual behavior, intravenous (IV) drug use, recent travel, and
occupational exposure. He was subsequently admitted with a
diagnosis of anemia with hemoglobin of 7.1 g/dL and sepsis
secondary to presumed pneumonia.
On admission, the patient received 4 units of packed red blood
cells for anemia. *e patient was also noted to have
thrombocytopenia with platelet count of 48,000/mcL; thus, Eliquis
was held. Chest X-ray revealed a 7.4 cm opacity in the right lung
base as well as multiple right pulmonary nodules (Figure 1). A CT
chest showed similar findings with the addition of extensive bone
metastasis. *e patient was started on vancomycin and Zosyn for
sepsis while awaiting blood culture results. Infectious workup was
positive for Aspergillus fumigatus IgG, Aspergillus galactomannan
antigen
Hindawi Case Reports in Cardiology Volume 2018, Article ID 6927436,
4 pages https://doi.org/10.1155/2018/6927436
(Ag), Histoplasma Ag, Fungitell, and Blastomyces antibody (Ab).
Human immunodeficiency virus (HIV), herpes sim- plex virus (HSV),
and influenza A and B serologies were negative. Blood cultures were
negative for viruses, bacteria, and fungi. Infectious diseases were
consulted. *e patient subsequently underwent a bronchoscopy, with
lavage speci- mens returning positive for Aspergillus Ag but
negative for pneumocystis pneumonia, HSV, bacteria, fungus
including Histoplasma, and malignant cells. *e patient was then di-
agnosed with presumed subacute invasive pulmonary as- pergillus.
Antibiotics were then discontinued, and the patient was discharged
with voriconazole for a 6-week duration.
Two days after discharge, he was admitted for atrial fibrillation
with rapid ventricular rate. A transthoracic echocardiogram (TTE)
was performed and showed a highly mobile 5 cm mass involving the
tricuspid valve with variable involvement of the right atrium and
right ventricle (Figure 2). *e ejection fraction was preserved.
Infectious diseases and oncology were then consulted. *e patient
remained on voriconazole, and Zytiga was discontinued as his
prostate cancer was castration sensitive, per oncology. CT surgery
was consulted and performed sternotomy with resection of the mass,
portions of the right atrium and ventricle, and tricuspid valve on
day 2 of admission. *e excised mass was pale yellow and pink,
irregularly shaped, fragmented, bulky, and approximately 3× 2×1.3
cm (Figure 3). Pathology from the mass and tricuspid valve showed
necrotic debris with acute inflammation and abundant fungal hyphae
(Figure 4).
Cultures obtained from tissue in the operating room were positive
for Aspergillus fumigatus and negative for bacteria and
viruses.
*e patient did well postoperatively. He was extubated to nasal
cannula within 12 hours; however, he remained on pressor support.
Voriconazole was continued. On day 4 of admission, he developed
septic shock, renal failure with oliguria and acidosis, and shock
liver requiring increased pressor support. He continued to
deteriorate the next day requiring endotracheal intubation and
ventilator support. On day 5 of admission, the patient developed
ventricular tachy- cardia followed by pulseless electrical
activity. Shortly there- after, he was pronounced dead.*e cause of
death was invasive aspergillosis-induced septic shock with
multiorgan failure.
3. Discussion
Aspergilloma of the heart is a rare disease that carries a very
poor prognosis. On review of the current literature, only a small
number of cases have been reported. *ese cases include an invasive
aspergillus of the interventricular sep- tum in an allogenic stem
cell transplant patient [3], aspergilloma involving all four
chambers of the heart [4], aspergillosis presenting as a
pedunculated mass with mul- tiple nodules on the left ventricular
wall in an acute lym- phoblastic leukemia patient [5], a large
right ventricular aspergilloma in a young man on chemotherapy for
acute myelogenous leukemia [6], an incidental finding of a tri-
cuspid valve aspergilloma after abdominal surgery [7], and the
three cases described in the correspondence by Wiwa- nitkit and
Wiwanitkit [8]. Of note, all except for one of the aforementioned
cases resulted in death within days to weeks after diagnosis.
Fungal endocarditis alone, without involvement of the surrounding
cardiac structure, is associated with a mortality rate of at least
50% with an average survival period of 11 days [9]. Fungal
endocarditis has also recently been shown to have increasing
prevalence with medical and surgical ad- vancements [1, 2].
Historically, the main risk factors for developing fungal
endocarditis included previous valve sur- gery, history of
prosthetic valve endocarditis, prolonged use of antibiotics,
rheumatic heart disease, and IV drug use [1].
Figure 1: CXR showing multiple right pulmonary nodules.
Figure 2: Transthoracic echocardiogram showing a mass involving the
tricuspid valve and both the right atrium and ventricle.
Figure 3: Right atrial and tricuspid ventricular mass.
2 Case Reports in Cardiology
Most recent studies suggest that these characteristics have changed
and that fungal endocarditis now more commonly affects
immunocompromised patients, patients with prosthetic valves and
central venous catheters, and those on broad-spectrum antibiotics
[1, 2]. Of note,Aspergillus endocarditis is mostly found on aortic
or mitral prosthetic valves [10] and has a mortality rate of
approximately 80% [2].
Prolonged fever, as seen in the described case, is the most common
presenting feature; however, some patients may present with new or
changing heart murmur, chest pain, cough, dyspnea, hemoptysis,
weakness, or generalized pain. Hemorrhagic black skin lesions have
been reported in As- pergillus endocarditis [11]. Such symptoms in
combination with leukocytosis, anemia, and thrombocytopenia may
also be suggestive of fungal septicemia. As discussed earlier, an
immunocompromised state, neutropenia, recent history of long-term
central venous catheter, prosthetic heart valve, steroid use,
prolonged antibiotic therapy, recent prolonged hospitalization,
parenteral nutrition, immunocompromised status, and IV drug use
predispose patients to an invasive fungal infection.
With the diverse symptoms and risk factors, the di- agnosis of
fungal endocarditis is rather challenging and can be easily delayed
without a high clinical suspicion, especially given that fungal
pathogens are slow growing. Diagnosis is further complicated as the
majority of fungi are not detected in blood cultures. Aspergillus,
in particular, is positive in 4–30% of blood cultures in cases of
Aspergillus endocarditis [2, 12]. Some reviews have also suggested
testing for gal- actomannan antigen, which is released when
Aspergillus proliferates [1, 12]. TTE is a valuable diagnostic tool
in diagnosing endocarditis and has been shown to identify 89% and
76.5% of the vegetations in native and prosthetic valves,
respectively [2]. Although vegetations seen on TTE may not
distinguish between bacterial versus fungal etiology, fungal
vegetations are typically characterized as a large, bulky, highly
mobile mass, as seen in the described case, and cause an increased
risk of embolic events, more commonly af- fecting the brain. Still,
many cases of fungal endocarditis are diagnosed during surgery or
autopsy.
Upon diagnosing fungal invasion of the heart, a multi- disciplinary
team involving cardiology, infectious diseases,
and cardiovascular surgery is necessary. Most recent reviews as
well as Infectious Diseases Society of America (IDSA) guidelines
favor a combined medical and early surgical intervention for
treatment of Aspergillus endocarditis, pericarditis, and
myocarditis. Surgical valve replacement in addition to systemic
antifungal therapy was noted to be pertinent to survival due to
poor prognosis and risk of relapse in patients receiving only
pharmacological therapy, decreased effect of antifungal medication
on fungal vege- tations, large vegetations possibly compromising
cardiac function, and the risk of embolic events [1, 12]. Per IDSA,
the recommended initial antifungal agents are voriconazole or
liposomal amphotericin B 3–5mg/kg/day, followed by lifelong
antifungal treatment postsurgical valve replacement [13].
Amphotericin B is preferred for patients with hepatic insufficiency
[12]. Some have proposed using caspofungin in addition to
voriconazole and amphotericin [14]; however, the use of combining
antifungal therapies has not been shown to be superior to
monotherapy [13]. In the described case, the patient was already on
voriconazole and underwent surgical resection.
*e differential diagnosis for the cardiac mass beyond a fungal
etiology includes thrombus, primary cardiac tumor, myxoma,
metastatic lesion, and lymphoma. *ough the patient had new-onset
atrial fibrillation, a thrombus was unlikely as he had been on
apixaban for approximately 6-7 months. Prostate cancer does not
typically metastasize to the heart; thus, metastasis was also
unlikely. Given the patient’s immunocompromised state, being on
steroids, and recent diagnosis of invasive pulmonary aspergillosis,
the clinical suspicion for a fungal mass was high. Hematogenous
spread of invasive pulmonary aspergillus was considered in the
development of cardiac aspergilloma. *e spread of invasive
pulmonary aspergillus to the heart is very rare and is as- sociated
with a high mortality estimated to be as high as 80–90% [15], which
is approximately the same mortality rate of having Aspergillus
endocarditis alone, despite aggressive pharmacological and surgical
interventions [2]. However, the hematogenous spread of invasive
pulmonary aspergillus would be expected to invade the left cardium
rather than the right, as seen in our patient.
In considering the described case, prior to discovering the cardiac
aspergilloma, the patient was already on antifungal
(a) (b)
Figure 4: Specimen of the mass with H&E stain (a) and GMS stain
highlighting fungal elements (b).
Case Reports in Cardiology 3
therapy. Furthermore, once a fungal mass was suspected, the patient
underwent surgery and continued antifungal treatment as per
recommendations. *e overall outcome, nonetheless, was grim.
Cardiac aspergilloma remains a rare yet deadly disease that carries
a high mortality rate despite aggressive phar- macological and
surgical interventions. Decreasing the mortality rate remains a
challenging task, given the nature of the disease and diagnostic
barriers to detecting the disease early on.While innovative
molecular methods can detect the diagnosis sooner than was
previously possible, clinical suspicion remains the key to
diagnosing the disease. Early clinical suspicion will lead to early
treatment, and earlier treatment will presumably result in
decreased mortality.
Conflicts of Interest
*e authors declare that there are no conflicts of interest
regarding the publication of this paper.
Acknowledgments
*e authors thank Dr. Janeen N. Buonaccorsi for assistance with
providing the pathology slides for the case report and Dr. Matthew
Mischler, Assistant Professor at University of Illinois College of
Medicine at Peoria, for comments that greatly helped with the
manuscript.
References
[1] P. Tattevin, M. Revest, A. Lefort, C. Michelet, and O.
Lortholary, “Fungal endocarditis: current challenges,”
International Journal of Antimicrobial Agents, vol. 44, no. 4, pp.
290–294, 2014.
[2] L. C. Pierrotti and L. M. Baddour, “Fungal endocarditis,
1995–2002,” Chest, vol. 122, no. 1, pp. 302–310, 2002.
[3] M. Paul, A. Schuster, S. T. Hussain, E. Nagel, and A.
Chiribiri, “Invasive aspergillosis, extensive cardiac involvement
dem- onstrated by cardiac magnetic resonance,” Circulation, vol.
126, no. 14, pp. 1780–1783, 2012.
[4] S. O. Soman, G. Vijayaraghavan, N. P. Padmaja, A. R.Warrier,
and M. Unni, “Aspergilloma of the heart,” Indian Heart Journal,
vol. 66, no. 2, pp. 238–240, 2014.
[5] J. Alvarez Rubiolvarez, J. Sierra Quiroga, C. Rubio Taboada, A.
Fernandez Gonzalez, F. Martinon Torres, and J. Garcia- Bengochea,
“Cardiac aspergillosis with pedunculated mass in the left
ventricle,” Texas Heart Institute Journal, vol. 31, no. 4, pp.
439–441, 2004.
[6] H.W. Chou, M. K. Chuang, and Y. S. Chen, “Rapid recurrence of
right ventricular aspergilloma,” European Journal of Cardio-)oracic
Surgery, vol. 44, no. 5, p. 965, 2013.
[7] M. K. Singla, A. Shrivastava, K. C. Mukherjee, and K. Sodhi,
“Potentially fatal tricuspid valve aspergilloma detected after
laparoscopic abdominal surgery,” Southern African Journal of
Anaesthesia and Analgesia, vol. 17, no. 3, pp. 266–268, 2011.
[8] S. Wiwanitkit and V. Wiwanitkit, “Cardiac aspergilloma,” Indian
Heart Journal, vol. 67, no. 3, p. 288, 2015.
[9] M. E. Ellis, H. Al-Abdely, A. Sandridge, W. Greer, and W.
Ventura, “Fungal endocarditis: evidence in the world literature
1965–1995,” Clinical Infectious Diseases, vol. 32, no. 1, pp.
50–62, 2001.
[10] A. C. Pasqualotto and D. W. Denning, “Post-operative
aspergillosis,” Clinical Microbiology and Infection, vol. 12, no.
11, pp. 1060–1076, 2006.
[11] G. M. Varghese and J. D. Sobel, “Fungal endocarditis,” Current
Infectious Disease Reports, vol. 10, no. 4, pp. 275–279,
2008.
[12] A. K. Pasha, J. Z. Lee, S. W. Low, H. Desai, K. S. Lee, andM.
Al Mohajer, “Fungal endocarditis: update on diagnosis and
management,” )e American Journal of Medicine, vol. 129, no. 10, pp.
1037–1043, 2016.
[13] T. F. Patterson, G. R. *ompson III, D. W. Denning et al.,
“Practice guidelines for the diagnosis and management of
aspergillosis: 2016 Update by the Infectious Diseases Society of
America,” Clinical Infectious Diseases, vol. 63, no. 4, pp. e1–
e60, 2016.
[14] S. M. Yuan, “Fungal endocarditis,” Brazilian Journal of
Cardiovascular Surgery, vol. 31, no. 3, pp. 252–255, 2016.
[15] B. Sulik-Tyszka, P. Kacprzyk, K. Madry, B. Ziarkiewicz-
Wroblewska, W. Jedrzejczak, and M. Wroblewska, “Asper- gillosis of
the heart and lung and review of published reports on fungal
endocarditis,” Mycopathologia, vol. 181, no. 7-8, pp. 583–588,
2016.
4 Case Reports in Cardiology
Stem Cells International
Hindawi www.hindawi.com Volume 2018
The Scientific World Journal
Journal of
Hindawi www.hindawi.com Volume 2018
Volume 2018 Hindawi www.hindawi.com